Cargando…

Communicating statin evidence to support shared decision-making

BACKGROUND: The practice of clinical medicine rests on a foundation of ethical principles as well as scientific knowledge. Clinicians must artfully balance the principle of beneficence, doing what is best for patients, with autonomy, allowing patients to make their own well-informed health care deci...

Descripción completa

Detalles Bibliográficos
Autores principales: Barrett, Bruce, Ricco, Jason, Wallace, Margaret, Kiefer, David, Rakel, Dave
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4822230/
https://www.ncbi.nlm.nih.gov/pubmed/27048421
http://dx.doi.org/10.1186/s12875-016-0436-9
_version_ 1782425739790909440
author Barrett, Bruce
Ricco, Jason
Wallace, Margaret
Kiefer, David
Rakel, Dave
author_facet Barrett, Bruce
Ricco, Jason
Wallace, Margaret
Kiefer, David
Rakel, Dave
author_sort Barrett, Bruce
collection PubMed
description BACKGROUND: The practice of clinical medicine rests on a foundation of ethical principles as well as scientific knowledge. Clinicians must artfully balance the principle of beneficence, doing what is best for patients, with autonomy, allowing patients to make their own well-informed health care decisions. The clinical communication process is complicated by varying degrees of confidence in scientific evidence regarding patient-oriented benefits, and by the fact that most medical options are associated with possible harms as well as potential benefits. DISCUSSION: Evidence-based clinical guidelines often neglect patient-oriented issues involved with the thoughtful practice of shared decision-making, where individual values, goals, and preferences should be prioritized. Guidelines on the use of statin medications for preventing cardiovascular events are a case in point. Current guidelines endorse the use of statins for people whose 10-year risk of cardiovascular events is as low as 7.5 %. Previous guidelines set the 10-year risk benchmark at 20 %. Meta-analysis of randomized trials suggests that statins can reduce cardiovascular event rates by about 25 %, bringing 10-year risk from 7.5 to 5.6 %, for example, or from 20 to 15 %. Whether or not these benefits should justify the use of statins for individual patients depends on how those advantages are valued in comparison with disadvantages, such as side effect risks, and with inconveniences associated with taking a pill each day and visiting clinicians and laboratories regularly. CONCLUSIONS: Whether or not the overall benefit-harm balance justifies the use of a medication for an individual patient cannot be determined by a guidelines committee, a health care system, or even the attending physician. Instead, it is the individual patient who has a fundamental right to decide whether or not taking a drug is worthwhile. Researchers and professional organizations should endeavor to develop shared decision-making tools that provide up-to-date best evidence in easily understandable formats, so as to assist clinicians in helping their patients to make the decisions that are right for them.
format Online
Article
Text
id pubmed-4822230
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-48222302016-04-06 Communicating statin evidence to support shared decision-making Barrett, Bruce Ricco, Jason Wallace, Margaret Kiefer, David Rakel, Dave BMC Fam Pract Debate BACKGROUND: The practice of clinical medicine rests on a foundation of ethical principles as well as scientific knowledge. Clinicians must artfully balance the principle of beneficence, doing what is best for patients, with autonomy, allowing patients to make their own well-informed health care decisions. The clinical communication process is complicated by varying degrees of confidence in scientific evidence regarding patient-oriented benefits, and by the fact that most medical options are associated with possible harms as well as potential benefits. DISCUSSION: Evidence-based clinical guidelines often neglect patient-oriented issues involved with the thoughtful practice of shared decision-making, where individual values, goals, and preferences should be prioritized. Guidelines on the use of statin medications for preventing cardiovascular events are a case in point. Current guidelines endorse the use of statins for people whose 10-year risk of cardiovascular events is as low as 7.5 %. Previous guidelines set the 10-year risk benchmark at 20 %. Meta-analysis of randomized trials suggests that statins can reduce cardiovascular event rates by about 25 %, bringing 10-year risk from 7.5 to 5.6 %, for example, or from 20 to 15 %. Whether or not these benefits should justify the use of statins for individual patients depends on how those advantages are valued in comparison with disadvantages, such as side effect risks, and with inconveniences associated with taking a pill each day and visiting clinicians and laboratories regularly. CONCLUSIONS: Whether or not the overall benefit-harm balance justifies the use of a medication for an individual patient cannot be determined by a guidelines committee, a health care system, or even the attending physician. Instead, it is the individual patient who has a fundamental right to decide whether or not taking a drug is worthwhile. Researchers and professional organizations should endeavor to develop shared decision-making tools that provide up-to-date best evidence in easily understandable formats, so as to assist clinicians in helping their patients to make the decisions that are right for them. BioMed Central 2016-04-06 /pmc/articles/PMC4822230/ /pubmed/27048421 http://dx.doi.org/10.1186/s12875-016-0436-9 Text en © Barrett et al. 2016 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Debate
Barrett, Bruce
Ricco, Jason
Wallace, Margaret
Kiefer, David
Rakel, Dave
Communicating statin evidence to support shared decision-making
title Communicating statin evidence to support shared decision-making
title_full Communicating statin evidence to support shared decision-making
title_fullStr Communicating statin evidence to support shared decision-making
title_full_unstemmed Communicating statin evidence to support shared decision-making
title_short Communicating statin evidence to support shared decision-making
title_sort communicating statin evidence to support shared decision-making
topic Debate
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4822230/
https://www.ncbi.nlm.nih.gov/pubmed/27048421
http://dx.doi.org/10.1186/s12875-016-0436-9
work_keys_str_mv AT barrettbruce communicatingstatinevidencetosupportshareddecisionmaking
AT riccojason communicatingstatinevidencetosupportshareddecisionmaking
AT wallacemargaret communicatingstatinevidencetosupportshareddecisionmaking
AT kieferdavid communicatingstatinevidencetosupportshareddecisionmaking
AT rakeldave communicatingstatinevidencetosupportshareddecisionmaking